FDA ARTHRITIS ADVISORY-COMMITTEE MEETING - THERAFECTIN - ROLE OF ARTHRITIS ADVISORY-COMMITTEE IN FDA REVIEW PROCESS - PERSONNEL CHANGES - ISSUES OF OVER-THE-COUNTER SWITCHING

被引：0

|

作者：

FURST, DE ^{[1
]}

PAULUS, HE ^{[1
]}

机构：

[1] VIRGINIA MASON RES CTR,CLIN RES PROGRAMS,SEATTLE,WA 98101

来源：

ARTHRITIS AND RHEUMATISM | 1994年 / 37卷 / 09期

关键词：

D O I：

10.1002/art.1780370921

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

收藏

页码：1408 / 1409

页数：2

相关论文

共 26 条

[21] Labelling news from the US FDA's Arthritis Advisory Committee
Reactions Weekly, 2003, 942 (1) : 2 - 2
[22] FDA-ARTHRITIS-ADVISORY-COMMITTEE MEETING - GUIDELINES FOR CLINICAL-EVALUATION OF THERAPIES FOR SCLERODERMA
PAULUS, HE
ARTHRITIS AND RHEUMATISM, 1992, 35 (07): : 835 - 836
[23] 1ST INFECTION-FIGHTING MONOCLONAL-ANTIBODIES SCRUTINIZED BY FDA ADVISORY-COMMITTEE MEMBERS
MARWICK, C
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (15): : 2050 - &
[24] INTELLECTUAL PROPERTY ISSUES IN THE LIBRARY NETWORK CONTEXT - PROCEEDINGS OF THE LIBRARY-OF-CONGRESS NETWORK ADVISORY-COMMITTEE MEETING MARCH 23-25, 1988
WALL, RA
JOURNAL OF DOCUMENTATION, 1990, 46 (03) : 276 - 278
[25] FDA-ARTHRITIS-ADVISORY-COMMITTEE MEETING - SERIOUS GASTROINTESTINAL TOXICITY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS - DRUG-CONTAINING RENAL AND BILIARY STONES - DICLOFENAC AND CARPROFEN APPROVED
PAULUS, HE
ARTHRITIS AND RHEUMATISM, 1988, 31 (11): : 1450 - 1451
[26] Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages
Wen, Shihua
He, Weili
Evans, Scott R.
Quartey, George
Norton, Jonathan D.
Chuang-Stein, Christy
Jiang, Qi
Ma, Haijun
Bhattacharya, Mondira
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (04): : 409 - 416